Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from ADMA Biologics ( (ADMA) ) is now available.
On May 4, 2026, ADMA Biologics announced that the U.S. Food and Drug Administration approved a supplemental Biologics License Application to expand the label for its intravenous immune globulin product ASCENIV to include pediatric immune compromised patients with primary humoral immunodeficiency aged two years and older. The decision, which fulfills a post-marketing pediatric assessment commitment and lowers the prior age threshold from 12 years, broadens ASCENIV’s addressable patient base and allows ADMA to intervene earlier in the treatment course of younger PI patients, potentially strengthening the product’s competitive position in the immune globulin market and reinforcing the company’s execution track record in complex pediatric clinical programs.
ADMA highlighted the collaboration of the primary immunodeficiency community, treating physicians and participating families in completing the required pediatric trials that supported the expanded indication. The company’s leadership framed the approval as a strategic milestone that may drive greater utilization of its differentiated, patented IVIG therapy in the pediatric setting, with implications for both clinical practice in managing immune compromised children and for ADMA’s growth prospects within the specialty biologics segment.
The most recent analyst rating on (ADMA) stock is a Buy with a $21.00 price target. To see the full list of analyst forecasts on ADMA Biologics stock, see the ADMA Stock Forecast page.
Spark’s Take on ADMA Stock
According to Spark, TipRanks’ AI Analyst, ADMA is a Neutral.
Score is driven by strong fundamentals and upbeat multi-year guidance (rapid revenue/margin expansion and improved leverage). It is tempered by very weak technical momentum (price far below key moving averages with negative MACD) and only moderate valuation support at ~29.6x earnings, alongside a 2025 step-down in cash conversion.
To see Spark’s full report on ADMA stock, click here.
More about ADMA Biologics
ADMA Biologics, Inc. is a U.S.-based, end-to-end commercial biopharmaceutical company focused on manufacturing, marketing and developing specialty plasma-derived biologics for immunodeficient and immune compromised patients at risk for infection. The company markets three FDA-approved plasma-derived products—ASCENIV, BIVIGAM and NABI-HB—and operates its own FDA-licensed plasma fractionation facility and source plasma collection network in Boca Raton, Fla., targeting niche patient populations and infectious disease prevention.
Average Trading Volume: 6,130,793
Technical Sentiment Signal: Hold
Current Market Cap: $2.44B
Learn more about ADMA stock on TipRanks’ Stock Analysis page.